DEVELOPMENT OF BREAST-SPECIFIC ANTIBODIES

Information

  • Research Project
  • 3493424
  • ApplicationId
    3493424
  • Core Project Number
    R43CA060329
  • Full Project Number
    1R43CA060329-01
  • Serial Number
    60329
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/5/1993 - 31 years ago
  • Project End Date
    9/4/1993 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    3/5/1993 - 31 years ago
  • Budget End Date
    9/4/1993 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/5/1993 - 31 years ago
Organizations

DEVELOPMENT OF BREAST-SPECIFIC ANTIBODIES

The effectiveness of the currently available cancer chemotherapy is severely limited due to side effects to healthy tissues. It is widely believed that the targeted delivery of cytotoxic effector molecules to the tumor tissue could greatly improve the anticancer effect. The first step in developing this type of therapy for the treatment of breast cancer is the identification of targeting vehicles, such as monoclonal antibodies which bind specifically to breast tumor tissue. Previous work has identified several antigens expressed on breast tumors but none of these are ideally suited as targets for immunotoxins. If the immunoconjugate therapy is to be effective, it is of absolute importance that the antigen is cell specific, expressed on the surface of the cell and is not shed into the sera. We propose a novel method that will should lead to the identification of breast tumor specific cell surface antigens. Subtractive hybridization has been used successfully to identify differentially expressed genes and we propose to apply this methodology to create a cDNA library that is highly enriched in sequences that encode breast tumor specific antigens. Expression of this library in a murine cell line will create a novel set of antigens that should upon immunization lead to antibodies with the desired breast tumor restricted specificity.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    IMMUNOGEN, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES